Aims: Pulmonary arterial hypertension (PAH) is a serious disease that affects both the pulmonary vasculature and the right ventricle (RV). Current treatments options are insufficient. The cardiac neuregulin (NRG)-1/ErbB system is deregulated during heart failure, and treatment with recombinant human NRG-1 (rhNRG-1) has been shown to be beneficial in animal models and in patients with left ventricle (LV) dysfunction. This study aimed to evaluate the effects of rhNRG-1 in RV function and pulmonary vasculature in monocrotalineinduced PAH and RV hypertrophy (RVH).
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In this work, we tested the effect of rhNRG-1 treatment in a rat model of MCT-induced PAH and RV overload. Consistent with our hypothesis, rhNRG-1attenuated the severity of this disease, as evident from the salutary effects of rhNRG-1 on pulmonary and RV remodelling and overall cardiac function. Beneficial effects of rhNRG-1 were evident both at the functional and at the histological/structural level. Furthermore, using a model of pressure loading of the RV without PAH, we also demonstrated that rhNRG-1 treatment has direct beneficial effects on RV structure, by reducing hypertrophy and fibrosis.
The cardiac NRG-1/ErbB system has been intensely studied, and there is compelling evidence that this system is activated during compensated LV failure 8 . Treatment of various animal models with LV dysfunction has resulted in improved cardiac function, LV remodelling and reduced heart failure mortality 10-15, 24, 25 , and has instigated ongoing clinical trials with NRG-1 in heart failure 16, 17 . Although it is generally believed that beneficial effects of NRG-1 in heart failure mainly result from direct effects on cardiomyocytes 25, 26 and, perhaps, on cardiac fibroblasts 10 , the physiological effects of NRG-1 may be more pleiotropic, including effects on vascular endothelial cells 27, 28 , vascular smooth muscle cells 19 and inflammatory cells 29 .
In line with these observations, the favourable effects of NRG-1 observed in the present study seem to result from effects on both the pulmonary vasculature (MCT model) and directly on by guest on October 28, 2015
Downloaded from the RV myocardium (PAB model). Both pulmonary arterial medial hypertrophy and pulmonary arterial endothelial dysfunction were markedly attenuated by NRG-1. This led to reduction of pulmonary arterial resistance, RV afterload and consequently of RV hypertrophy and RV contractility. Although the precise mechanisms of these beneficial effects of NRG-1 on the pulmonary endothelium and vasculature remain to be deciphered, inhibitory effects of rhNRG-1 on platelet-derived growth factor induced smooth muscle cell proliferation 19 , and stimulatory actions on nitric oxide synthesis may participate 26, 30 .
Lung inflammation is associated with the development of PAH 31 , and inflammatory markers as TNF-α and IL-6 are increased in MCT-induced PAH 32 . Our finding that rhNRG-1 treatment did not attenuate lung inflammation shows that the improvement of pulmonary and RV function and structure was not achieved through attenuation of an acute inflammatory response in MCT-induced PAH 23 . In the same perspective and regardless of previous evidence associating inflammatory cardiomyopathy to MCT-induced PAH 23 , we did not observed TNF-α and IL-6 altered expression in the RV of MCT animals, which suggests that RV myocardial inflammation does not seem to play a role in our experimental setting.
Despite this observation, PAH-associated systemic inflammation 33, 34 
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